![Thomas Schlumpberger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Thomas Schlumpberger worked as the Chief Executive Officer at Pictor Ltd. from 2020 to 2022, and as the Chief Executive Officer & Director at Nanomix Corp.
from 2022 to 2023.
Prior to that, he was the Executive Vice President-Diagnostics at Anixa Biosciences, Inc. in 2019.
He also worked as the Vice President-Diagnostics at Singulex, Inc. and as the Vice President-Business Development at Inivata, Inc. from 2018 to 2019.
Dr. Schlumpberger holds a doctorate degree from the University of California, Berkeley and a graduate degree from Technische Universität München.
Anciens postes connus de Thomas Schlumpberger
| Sociétés | Poste | Fin |
|---|---|---|
| NANOMIX CORPORATION | Directeur Général | 02/11/2023 |
Pictor Ltd.
 Pictor Ltd. BiotechnologyHealth Technology Develops a technology for multiplexed testing for blood and other biological fluids | Directeur Général | 01/01/2022 |
| ANIXA BIOSCIENCES, INC. | Corporate Officer/Principal | 01/07/2020 |
Inivata, Inc.
 Inivata, Inc. Part of NeoGenomics, Inc., Inivata, Inc. is a cancer diagnostic, pharmaceutical services, and information service company. The company is based in Jefferson City, MO. NeoGenomics Laboratories has been providing laboratory diagnostics and clinical trial services for over 18 years. The company works in partnership with cancer care teams to provide vital oncology answers that transform the lives of people living with cancer. NeoGenomics offers a comprehensive menu of diagnostic services, ranging from traditional to state-of-the-art testing, to support a personalized test approach. The company is committed to improving patient care through communication, accuracy, reliability, and efficiency. NeoGenomics serves oncologists, pathologists, pharmaceutical companies, and academic centers in their pursuit of providing better futures for people living with cancer. | Corporate Officer/Principal | 01/08/2019 |
Singulex, Inc.
 Singulex, Inc. Medical SpecialtiesHealth Technology Operates as an immunodiagnostics company | Corporate Officer/Principal | - |
Formation de Thomas Schlumpberger
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
2
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Anixa Biosciences, Inc.
 Anixa Biosciences, Inc. BiotechnologyHealth Technology Develops therapies and vaccines for oncology and infectious disease | Health Technology |
Singulex, Inc.
Singulex, Inc. Medical SpecialtiesHealth Technology Operates as an immunodiagnostics company | Health Technology |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Technische Universität München
 Technische Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pictor Ltd.
Pictor Ltd. BiotechnologyHealth Technology Develops a technology for multiplexed testing for blood and other biological fluids | Health Technology |
Nanomix Corp.
 Nanomix Corp. Medical SpecialtiesHealth Technology Develops, manufactures and commercializes point-of-care diagnostic tests | Health Technology |
Inivata, Inc.
Inivata, Inc. Part of NeoGenomics, Inc., Inivata, Inc. is a cancer diagnostic, pharmaceutical services, and information service company. The company is based in Jefferson City, MO. NeoGenomics Laboratories has been providing laboratory diagnostics and clinical trial services for over 18 years. The company works in partnership with cancer care teams to provide vital oncology answers that transform the lives of people living with cancer. NeoGenomics offers a comprehensive menu of diagnostic services, ranging from traditional to state-of-the-art testing, to support a personalized test approach. The company is committed to improving patient care through communication, accuracy, reliability, and efficiency. NeoGenomics serves oncologists, pathologists, pharmaceutical companies, and academic centers in their pursuit of providing better futures for people living with cancer. |
Choisissez Zonebourse 
